BANZATO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.793
AS - Asia 605
EU - Europa 386
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 1
OC - Oceania 1
Totale 4.803
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.786
CN - Cina 313
SG - Singapore 170
IT - Italia 83
VN - Vietnam 75
FI - Finlandia 74
DE - Germania 63
SE - Svezia 53
GB - Regno Unito 39
FR - Francia 26
UA - Ucraina 20
KR - Corea 18
NL - Olanda 13
BR - Brasile 12
IN - India 10
CA - Canada 6
IE - Irlanda 5
JP - Giappone 5
EU - Europa 4
RU - Federazione Russa 4
TW - Taiwan 4
BE - Belgio 3
HK - Hong Kong 2
LK - Sri Lanka 2
TR - Turchia 2
AO - Angola 1
AR - Argentina 1
AU - Australia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
IR - Iran 1
MX - Messico 1
NP - Nepal 1
PK - Pakistan 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 4.803
Salva come PNG Salva come JPEG
Città #
Fairfield 635
Chandler 361
Woodbridge 351
Ashburn 338
Houston 327
Ann Arbor 260
Cambridge 219
Seattle 217
Wilmington 187
Singapore 135
Beijing 97
Jacksonville 90
Boardman 79
Dong Ket 75
Princeton 75
San Diego 75
Santa Clara 46
Roxbury 44
Nanjing 41
Medford 40
Des Moines 39
Helsinki 26
Padova 23
Nanchang 17
Frankfurt am Main 15
New York 15
Guangzhou 14
Shenyang 14
Hebei 13
Seoul 13
Hefei 9
London 9
Milan 8
Norwalk 7
Redwood City 7
Dallas 6
Detroit 6
Jiaxing 6
Jinan 6
Tianjin 6
Changsha 5
Dublin 5
Washington 5
Dearborn 4
Indiana 4
Kunming 4
Munich 4
Rome 4
Taichung 4
Tokyo 4
Zhengzhou 4
Brussels 3
Cusano Milanino 3
Genoa 3
Ningbo 3
Ogden 3
Pune 3
Shanghai 3
Tappahannock 3
Bertinoro 2
Borås 2
Cherasco 2
Dehiwala 2
Gandhinagar 2
Haikou 2
Hounslow 2
Kharkiv 2
Leipzig 2
Pescara 2
Prescot 2
Saint Louis 2
Taizhou 2
Verona 2
Vicenza 2
Aarhus 1
Ancona 1
Bari 1
Barnaul 1
Belo Horizonte 1
Buffalo 1
Campo Grande 1
Cedar Falls 1
Chiswick 1
Chongqing 1
Clifton 1
Colombo 1
Columbus 1
Den Haag 1
Downers Grove 1
Duque de Caxias 1
Edinburgh 1
Falkenstein 1
Fenghua 1
Formosa 1
Fragneto Monforte 1
Geislingen an der Steige 1
Grenoble 1
Harbin 1
Hong Kong 1
Islamabad 1
Totale 4.078
Salva come PNG Salva come JPEG
Nome #
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. 170
(188)Rhenium-induced cell death and apoptosis in a panel of tumor cell lines 147
Laboratory testing for antiphospholipid syndrome 131
Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate 129
Diagnosis and therapy of antiphospholipid syndrome 128
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 120
The Paradox of the Lupus Anticoagulant: History and Perspectives 118
Interpretation of laboratory data and need for reference laboratories. 117
A YAP camera for the biodistribution of Re-188 conjugated with Hyaluronic-Acid in "in vivo" systems 116
APS - Diagnostics and challenges for the future 113
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 110
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 110
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer 109
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 108
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 108
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 106
Antiphospholipid syndrome: critical analysis of the diagnostic path 105
Novel types of carborane-carrier hyaluronan derivatives via "click chemistry". 101
Bioavailability of Tc-99m-Ha-paclitaxel complex [Tc-99m-ONCOFID-P] in mice using four different administration routes 100
Correct laboratory approach to APS diagnosis and monitoring 99
A paclitaxel-hyaluronan bioconjugate exerts a high in vivo therapeutic activity against ovarian cancer 98
Hydrosoluble, Metabolically Fragile Bioconjugates by Coupling Tetrabutylammonium Hyaluronan with 2′ Paclitaxel-4-Bromobutyrate: Synthesis and Antitumor Properties 97
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 97
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 94
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 94
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 93
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 91
Biokinetic and dosimetric studies of Re-188-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma 89
Detection of lupus anticoagulant in the era of direct oral anticoagulants 86
Secondary prevention in thrombotic antiphospholipid syndrome. 85
β2-Glycoprotein I Binds to Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 85
Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability 84
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 83
Laboratory Diagnostics of Antiphospholipid Syndrome 81
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 81
Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. 79
Radiopharmacokinetic and dosimetric studies of Re-188-HA: comparison with Re-188-HDD/lipiodol 78
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis 77
The challenges of lupus anticoagulants 73
Clinical Relevance of β2-Glycoprotein-I Plasma Levels in Antiphospholipid Syndrome (APS) 72
Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy 72
Risk-based secondary prevention of obstetric antiphospholipid syndrome. 71
Beta 2 glycoprotein I selectively inhibits the procoagulant function of thrombin: a novel physiologic anticoagulant mechanism in haemostasis 67
A mouse model of liver metastasis 66
What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? 65
Preliminary data on the evaluation of Rhenium-188 in radiotherapy application Hyaluronic Acid as vector for liver neoplasies and DNA damage induced by 188Re in vitro systems 65
The role of platelets in antiphospholipid syndrome 62
PN2S-PEG-BIOMOLECULE DERIVATIVES LABELED WITH TECHNETIUM-99m IN ABSENCE OF AN EXTERNAL REDUCING AGENT 60
Chemical Synthesis and Characterization of Wild-type and Biotinylated N-terminal Domain 1-64 of Beta2-glycoprotein I 56
Identifying novel thrombin interactions: Alpha-synuclein binds to thrombin exosites and inhibits thrombin-mediated platelet aggregation 50
Radiopharmacokinetic and dosimetric studies of 188Re-HA: comparation with 188Re-HHD/lipiodol 45
Effect of anti beta2-glycoprotein I Lupus Anticoagulant antibodies on clotting time in the presence of human umbilical vein endothelial cells 44
Novel thrombin interactions: alpha-synuclein binds thrombin exosites and inhibits thrombin-mediated platelet aggregation 38
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study 23
Totale 4.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.658
article - articoli 16.479
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.137
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020650 0 0 0 0 0 79 130 119 111 112 64 35
2020/2021574 39 42 23 43 15 54 35 50 86 38 41 108
2021/2022775 19 95 102 71 13 47 36 86 30 13 73 190
2022/2023642 129 83 10 73 106 78 0 52 67 7 28 9
2023/2024340 4 59 38 19 27 65 24 51 7 1 27 18
2024/2025402 8 69 79 52 164 30 0 0 0 0 0 0
Totale 4.846